Top

Published in:

01-03-2017 | Original Article

Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort

Authors: Hui Shi, Jia-lin Teng, Yue Sun, Xin-yao Wu, Qiong-yi Hu, Hong-lei Liu, Xiao-bing Cheng, Yu-feng Yin, Jun-na Ye, Pojen P. Chen, Cheng-de Yang

Published in: Clinical Rheumatology | Issue 3/2017

Abstract

This study aims to characterize the Chinese Han patients with anti-phospholipid syndrome (APS) and compare the data with those of the Euro-Phospholipid cohort. We conducted a single center study consisting of 252 patients with definite APS from 2000 to 2015. We analyzed the clinical and laboratory characteristics of our cohort and compared the data with those of the Euro-Phospholipid cohort. Our cohort consisted of 216 females and 36 males, with a mean age at entry into this study of 41 years (range 11–74 years). Of these patients, 69 (27.4%) patients had primary APS, and 183 (72.6%) had secondary APS (SAPS), including 163 (64.7%) patients had systemic lupus erythematosus (SLE). Thrombotic events occurred in 190 (75.4%) patients, and the most common ones were deep vein thrombosis (40.1%) and stroke (23.8%), which were similar to the reports of the Euro-Phospholipid cohort. In contrast, our cohort had less pulmonary embolism (6.7%). Among 93 females with 299 pregnancy episodes, the rates of early (<10 weeks) and late fetal loss (≥10 weeks) were, respectively, 37.8% and 24.4%. The latter was significantly higher than that of the Euro-Phospholipid cohort. Moreover, 7 APS nephropathy patients (characterized histopathologically by thrombotic microangiopathy) and 8 catastrophic APS patients were found in our cohort. Anti-cardiolipin antibodies (aCL) were detected in 169 (67.1%) patients, lupus anti-coagulant (LA) was detected in 83 (32.9%), and anti-β2 glycoprotein I antibodies (anti-β2GPI) in 148 (58.7%) patients. These results show that some clinical manifestations of APS may vary among different racial groups.

Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7(6):330–339. doi:10.1038/nrrheum.2011.52 CrossRefPubMed

Cervera R, Espinosa G (2012) Update on the catastrophic antiphospholipid syndrome and the "CAPS registry". Semin Thromb Hemost 38(4):333–338. doi:10.1055/s-0032-1304718 CrossRefPubMed

Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, Oku K, Kon Y, Horita T, Yasuda S, Koike T (2012) Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21(14):1506–1514. doi:10.1177/0961203312458469 CrossRefPubMed

Cervera R, Piette J, Font J, Khamashta M, Cervera R, Piette J, Font J, Khamashta M, Shoenfeld Y, Camps M, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni P, Derksen R, de Groot P, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris J, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa M, Hughes G, Ingelmo M (2002) Antiphospholipid syndrome—clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019–1027CrossRefPubMed

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306CrossRefPubMed

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 42:1309–1311CrossRefPubMed

Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Sr K, Liang MH, Luthra HS, Medsger TAJ, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315CrossRefPubMed

Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S et al (1993) Preliminary criteria for the classification of Sjogren’s syndrome. Results of a prospective concerted action supported by the European community. Arthritis Rheum 36(3):340–347CrossRefPubMed

10.

Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y, Catastrophic Antiphospholipid Syndrome Registry Project G (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (7):530–534

11.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50(8):2569–2579CrossRefPubMed

12.

Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737–1740. doi:10.1111/j.1538-7836.2009.03555.x CrossRefPubMed

13.

Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74(4):1185–1190PubMed

14.

McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK (1995) Incidence of systemic lupus erythematosus—race and gender differences. Arthritis Rheum 38:1260–1270CrossRefPubMed

15.

Zhang S, Wu Z, Li P, Bai Y, Zhang F, Li Y (2015) Evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-Beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome. Medicine 94(46):e2059. doi:10.1097/md.0000000000002059 CrossRefPubMedPubMedCentral

16.

Osio-Salido E, Manapat-Reyes H (2010) Epidemiology of systemic lupus erythematosus in Asia. Lupus 19(12):1365–1373. doi:10.1177/0961203310374305 CrossRefPubMed

17.

Huang SS, Liu Y, Jing ZC, Wang XJ, Mao YM (2016) Common genetic risk factors of venous thromboembolism in western and Asian populations. Genetics and molecular research : GMR 15(1):15017644. doi:10.4238/gmr.15017644 PubMed

18.

Tang L, Hu Y (2015) Ethnic diversity in the genetics of venous thromboembolism. Thromb Haemost 114(5):901–909. doi:10.1160/th15-04-0330 CrossRefPubMed

19.

Zakai NA, McClure LA (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9(10):1877–1882. doi:10.1111/j.1538-7836.2011.04443.x CrossRefPubMed

20.

White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93(2):298–305. doi:10.1160/th04-08-0506 PubMed

21.

Cheuk BL, Cheung GC, Cheng SW (2004) Epidemiology of venous thromboembolism in a Chinese population. The British journal of surgery 91(4):424–428. doi:10.1002/bjs.4454 CrossRefPubMed

22.

Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, Petterson TM, De Andrade M (2012) A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 10(8):1521–1531. doi:10.1111/j.1538-7836.2012.04810.x CrossRefPubMedPubMedCentral

23.

Ding Q, Yang L, Hassanian SM, Rezaie AR (2013) Expression and functional characterisation of natural R147W and K150del variants of protein C in the Chinese population. Thromb Haemost 109(4):614–624. doi:10.1160/th12-10-0760 CrossRefPubMedPubMedCentral

24.

Tang L, Wang HF, Lu X, Jian XR, Jin B, Zheng H, Li YQ, Wang QY, Wu TC, Guo H, Liu H, Guo T, Yu JM, Yang R, Yang Y, Hu Y (2013) Common genetic risk factors for venous thrombosis in the Chinese population. Am J Hum Genet 92(2):177–187. doi:10.1016/j.ajhg.2012.12.013 CrossRefPubMedPubMedCentral

25.

Jara LJ, Medina G, Vera-Lastra O, Barile L (2005) The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 14(8):607–612CrossRefPubMed

26.

Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016). Lancet (London, England) 388 (10053):1725–1774. doi:10.1016/s0140-6736(16)31575-6

27.

Li W, Zeng Chan W, Cui X, Xiao Feng L, Mao Sheng Y (2010) Genome-wide screening for risk loci of idiopathic recurrent miscarriage in a Han Chinese population: a pilot study. Reproductive sciences (Thousand Oaks, Calif) 17(6):578–584. doi:10.1177/1933719110364248 CrossRef

28.

Kolte AM, Nielsen HS, Moltke I, Degn B, Pedersen B, Sunde L, Nielsen FC, Christiansen OB (2011) A genome-wide scan in affected sibling pairs with idiopathic recurrent miscarriage suggests genetic linkage. Mol Hum Reprod 17(6):379–385. doi:10.1093/molehr/gar003 CrossRefPubMed

29.

Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM (1989) The “primary” antiphospholipid syndrome: major serological features. Medicine 68:366–374iCrossRefPubMed

30.

Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hughes GRV (1994) Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. AmJMed 96:3–9

31.

Kelly-Hayes M (2010) Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc 58(Suppl 2):S325–S328. doi:10.1111/j.1532-5415.2010.02915.x CrossRefPubMedPubMedCentral

32.

Tektonidou MG, Sotsiou F, Moutsopoulos HM (2008) Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 35(10):1983–1988PubMed

33.

Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61(1):29–36. doi:10.1002/art.24232 CrossRefPubMed

34.

Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242. doi:10.1111/j.1538-7836.2009.03674.x CrossRefPubMed

Title: Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort
Authors: Hui Shi
Jia-lin Teng
Yue Sun
Xin-yao Wu
Qiong-yi Hu
Hong-lei Liu
Xiao-bing Cheng
Yu-feng Yin
Jun-na Ye
Pojen P. Chen
Cheng-de Yang
Publication date: 01-03-2017
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 3/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3549-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas

Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart

Inflammatory biomarkers, disease activity index, and self-reported disability may be predictors of chronic arthritis after chikungunya infection: brief report

Two cases demonstrating thalidomide’s efficacy in refractory lupus nephritis

Uveitis in childhood-onset systemic lupus erythematosus patients: a multicenter survey

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page